Abstract
Ibrutinib, as the first Bruton's tyrosine kinase (Btk) inhibitor, has been shown to have clinically significant activity in leukemias and lymphomas. H......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
